Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitement amélioré pour les patients présentant un traitement aux opioïdes à long terme pour la douleur non cancer dans les soins primaires (Opi-Prim)

25 septembre 2026 mis à jour par: Thomas Kempen, Uppsala County Council, Sweden

Un traitement amélioré pour les patients présentant un traitement aux opioïdes à long terme pour la douleur non cancer dans les soins primaires (OPI-PRIM)

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

  • Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
  • Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
  • Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.

Aperçu de l'étude

Description détaillée

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

Type d'étude

Interventionnel

Inscription (Estimé)

110

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Gävleborg County
      • Gävle, Gävleborg County, Suède
        • Pas encore de recrutement
        • Region Gävleborg
        • Contact:
    • Södermanland County
      • Strängnäs, Södermanland County, Suède
        • Pas encore de recrutement
        • Region Sörmland
        • Contact:
    • Uppsala County
      • Uppsala, Uppsala County, Suède
        • Recrutement
        • Region Uppsala
        • Contact:
    • Örebro County
      • Örebro, Örebro County, Suède

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
  • Able to speak Swedish or English

Exclusion Criteria:

  • Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
  • No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
  • Using their opioids for cancer pain

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Control

Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

Comparateur actif: Intervention

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Pain interference
Délai: The primary outcome measure will be the difference in mean pain interference after 6 months.

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

The primary outcome measure will be the difference in mean pain interference after 6 months.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Pain intensity
Délai: After 3, 6 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse

After 3, 6 and 12 months
Symptoms of depression
Délai: After 3, 6 and 12 months

Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Symptoms of anxiety
Délai: After 3, 6 and 12 months

Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Patient satisfaction
Délai: After 3, 6 and 12 months

Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse

After 3, 6 and 12 months
Quality of life according to the 5-level EuroQol 5D
Délai: After 3, 6 and 12 months

Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.

After 3, 6 and 12 months
Opioid use
Délai: After 3, 6 and 12 months

Measured with as morphine equivalents: in mg.

After 3, 6 and 12 months
Symptoms of withdrawal
Délai: After 3, 6 and 12 months

Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse

After 3, 6 and 12 months
Pain interference
Délai: After 3 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

After 3 and 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 mars 2025

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

31 décembre 2028

Dates d'inscription aux études

Première soumission

26 février 2025

Première soumission répondant aux critères de contrôle qualité

26 février 2025

Première publication (Réel)

4 mars 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • Opi-Prim

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner